| Market Cap | 25.88M | P/E | 10.88 | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -6.22M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -6.00% |
| Sales | 8.91M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -29.00% |
| Dividend | N/A | Price/Book | 0.80 | EPS next 5Y | - | 52W High Chg | -47.00% |
| Recommedations | - | Quick Ratio | 3.96 | Shares Outstanding | 78.29M | 52W Low Chg | 3.00% |
| Insider Own | 4.01% | ROA | -15.53% | Shares Float | 76.19M | Beta | - |
| Inst Own | - | ROE | -21.42% | Shares Shorted/Prior | -/- | Price | 0.33 |
| Gross Margin | 40.04% | Profit Margin | -69.74% | Avg. Volume | 8,438 | Target Price | - |
| Oper. Margin | -88.27% | Earnings Date | Aug 7 | Volume | 500 | Change | 0.00% |
Ceapro Inc., a biotechnology company, engages in the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using proprietary technology, natural, and renewable resources in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of the technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also develops and commercializes active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. The company was incorporated in 1997 and is headquartered in Edmonton, Canada. As of June 3, 2024, Ceapro Inc. operates as a subsidiary of Aeterna Zentaris Inc.
